TREPPO, Elena
 Distribuzione geografica
Continente #
AS - Asia 1.027
NA - Nord America 934
EU - Europa 384
SA - Sud America 172
AF - Africa 26
OC - Oceania 4
AN - Antartide 1
Continente sconosciuto - Info sul continente non disponibili 1
Totale 2.549
Nazione #
US - Stati Uniti d'America 900
SG - Singapore 503
CN - Cina 167
BR - Brasile 144
VN - Vietnam 124
IT - Italia 103
HK - Hong Kong 102
RU - Federazione Russa 55
FR - Francia 45
DE - Germania 40
FI - Finlandia 24
KR - Corea 23
IN - India 22
GB - Regno Unito 20
CA - Canada 18
BD - Bangladesh 16
IE - Irlanda 14
AR - Argentina 13
AT - Austria 13
PL - Polonia 13
NL - Olanda 12
PK - Pakistan 11
JP - Giappone 10
SE - Svezia 10
ZA - Sudafrica 10
IQ - Iraq 9
UZ - Uzbekistan 7
ES - Italia 6
MX - Messico 6
BE - Belgio 5
CO - Colombia 5
ID - Indonesia 5
TR - Turchia 5
AE - Emirati Arabi Uniti 4
CR - Costa Rica 4
GR - Grecia 4
TG - Togo 4
BO - Bolivia 3
CZ - Repubblica Ceca 3
HR - Croazia 3
LK - Sri Lanka 3
NZ - Nuova Zelanda 3
OM - Oman 3
UA - Ucraina 3
CH - Svizzera 2
EC - Ecuador 2
EG - Egitto 2
JO - Giordania 2
LB - Libano 2
MA - Marocco 2
PS - Palestinian Territory 2
PT - Portogallo 2
PY - Paraguay 2
UY - Uruguay 2
AM - Armenia 1
AQ - Antartide 1
AU - Australia 1
BA - Bosnia-Erzegovina 1
BW - Botswana 1
CG - Congo 1
CI - Costa d'Avorio 1
CY - Cipro 1
DK - Danimarca 1
DM - Dominica 1
DO - Repubblica Dominicana 1
DZ - Algeria 1
EE - Estonia 1
ET - Etiopia 1
GH - Ghana 1
GP - Guadalupe 1
HN - Honduras 1
IR - Iran 1
JM - Giamaica 1
KE - Kenya 1
KZ - Kazakistan 1
LT - Lituania 1
MD - Moldavia 1
MY - Malesia 1
NO - Norvegia 1
RO - Romania 1
SA - Arabia Saudita 1
SN - Senegal 1
TH - Thailandia 1
TT - Trinidad e Tobago 1
VE - Venezuela 1
XK - ???statistics.table.value.countryCode.XK??? 1
Totale 2.549
Città #
Singapore 234
Ashburn 163
Hong Kong 94
San Jose 84
Council Bluffs 83
Beijing 71
Boardman 52
Ho Chi Minh City 34
Lauterbourg 33
Los Angeles 32
Chandler 29
Hefei 25
Hanoi 23
Seoul 23
Dallas 22
New York 21
Santa Clara 18
Redondo Beach 17
Helsinki 16
Milan 16
Frankfurt am Main 15
Dublin 14
São Paulo 14
Buffalo 13
The Dalles 13
Warsaw 13
Dong Ket 12
Ann Arbor 11
Belluno 11
Nuremberg 11
Wilmington 10
Düsseldorf 9
Woodbridge 9
Denver 8
Houston 8
Lappeenranta 8
Mumbai 8
Princeton 8
Stockholm 8
Tokyo 8
Udine 8
Amsterdam 7
Brooklyn 7
Fairfield 7
London 7
Seattle 7
Tashkent 7
Cambridge 6
Johannesburg 6
Lahore 6
Ogden 6
Toronto 6
Biên Hòa 5
Florence 5
Haiphong 5
Montreal 5
Taranto 5
Vienna 5
Athens 4
Atlanta 4
Brussels 4
Chennai 4
Da Nang 4
Jakarta 4
Lomé 4
Newark 4
Orem 4
Phoenix 4
Rimini 4
Trieste 4
Xi'an 4
Boston 3
Campinas 3
Chicago 3
Christchurch 3
Colombo 3
Crema 3
Guarulhos 3
Hải Dương 3
Jacksonville 3
Lucca 3
North Bergen 3
Querétaro 3
Rio de Janeiro 3
Rosario 3
Vũng Tàu 3
Albufeira 2
Amman 2
Ankara 2
Asunción 2
Basra 2
Belo Horizonte 2
Bergamo 2
Bắc Giang 2
Calgary 2
Can Tho 2
Charlotte 2
Codroipo 2
Des Moines 2
Dhaka 2
Totale 1.536
Nome #
Mepolizumab for Eosinophilic Granulomatosis With Polyangiitis: A European Multicenter Observational Study 115
Cryoglobulinemic vasculitis in primary Sjögren's Syndrome: Clinical presentation, association with lymphoma and comparison with Hepatitis C-related disease 114
Rituximab induction and maintenance in ANCA-associated vasculitis: State of the art and future perspectives 111
Efficacy and Safety of High-Dose Immunoglobulin-Based Regimen in Statin-Associated Autoimmune Myopathy: A Multi-Center and Multi-Disciplinary Retrospective Study 106
Data linkage analysis of giant cell arteritis in Italy: Healthcare burden and cost of illness in the Italian region of Friuli Venezia Giulia (2001–2017) 105
Systemic vasculitis: one year in review 2023 96
Sjögren's disease and systemic lupus erythematosus overlap syndrome as distinct entity at the crossroads of two autoimmune disorders: clinical characterisation from two Italian reference centres for both diseases 96
Validation of the Italian version of the ANCA-associated vasculitis patient-reported outcome (AAV-PRO) questionnaire 95
Safety of Biologic-DMARDs in Rheumatic Musculoskeletal Disorders: A Population-Based Study over the First Two Waves of COVID-19 Outbreak 94
The impact of two different rituximab-based strategies in cryoglobulinaemic vasculitis secondary to Sjögren's disease: a monocentric cohort study 94
Physical activity assessment with wearable devices in rheumatic diseases: a systematic review and meta-analysis 88
Healthcare and economic burden of ANCA-associated vasculitis in Italy: an integrated analysis from clinical and administrative databases 88
Unmet needs in ANCA-associated vasculitis: Physicians’ and patients’ perspectives 84
COVID-19 and Mixed Cryoglobulinemia Syndrome: Long-Term Survey Study on the Prevalence and Outcome, Vaccine Safety, and Immunogenicity 80
Normal-Appearing Salivary Gland Ultrasonography Identifies a Milder Phenotype of Primary Sjögren's Syndrome 78
Faster steroid-free remission with tocilizumab compared to methotrexate in giant cell arteritis: a real-life experience in two reference centres 78
Recent updates in the diagnosis and management of cryoglobulinemic vasculitis 78
Interstitial lung disease with and without progressive fibrosing phenotype in patients with idiopathic inflammatory myopathies: data from a large multicentric cohort 77
Age at diagnosis influences the clinical phenotype, treatment strategies and outcomes in patients with giant cell arteritis: results from the observational GCAGE study on a large cohort of 1004 patients 77
Systemic vasculitis: one year in review 2024 76
Systemic vasculitis: one year in review 2022 75
Management of mixed cryoglobulinemia with rituximab: evidence and consensus-based recommendations from the Italian Study Group of Cryoglobulinemia (GISC) 73
Risk of Cancer in Connective Tissue Diseases in Northeastern Italy over 15 Years 72
Treatment strategy introducing immunosuppressive drugs with glucocorticoids ab initio or very early in giant cell arteritis: A multicenter retrospective controlled study 69
Paraproteinemias Associated with Autoimmune Diseases 68
Timing of rituximab and immunoglobulin level influence the risk of death for COVID-19 in ANCA-associated vasculitis 64
Rheumatologic manifestations of Hepatitis C Virus 61
Mass-Forming Variants in Antineutrophil Cytoplasmic Antibody–Associated Vasculitis: Diagnostic Complexities in Granulomatous Disease. A Case Report 59
One year in review 2021: systemic vasculitis 56
One year in review 2020: vasculitis 55
The paradigm shift in ANCA-Associated vasculitis: Prime time for the complement targeting 52
Systemic vasculitis: one year in review 2025 49
The pre-clinical phase of giant cell arteritis: new clues in the pathogenesis of giant cell arteritis supporting emerging targets 44
Impact of mepolizumab on the AAV-PRO questionnaire in eosinophilic granulomatosis with polyangiitis: Data from a European multicentre study 33
Patients with anti-SAE+ dermatomyositis display refractory and difficult-to-treat skin manifestations: case series from two Italian cohorts and review of literature 26
Systemic vasculitis: one year in review 2026 6
Totale 2.692
Categoria #
all - tutte 11.901
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 11.901


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202113 0 0 0 0 0 0 0 0 0 0 0 13
2021/202258 4 2 6 4 0 0 9 6 0 10 7 10
2022/202394 10 4 11 5 10 15 0 5 15 11 4 4
2023/202498 15 10 9 3 13 3 1 4 9 11 8 12
2024/2025839 14 73 44 28 35 31 83 69 118 61 143 140
2025/20261.523 150 165 129 114 247 149 144 44 73 103 134 71
Totale 2.692